Neoplasms

Eye Diseases

All Conditions

Diseases and Abnormalities at or Before Birth

Rare Diseases

Retinoblastoma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Retinal Neoplasms

Eye Neoplasms

Eye Diseases, Hereditary

Retinal Diseases

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Etoposide

Carboplatin

Vincristine

Etoposide phosphate

Enzyme Inhibitors

Tubulin Modulators

Antimitotic Agents

CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection

chemotherapy together with/without 20mg/2ml carboplatin periocular injection

carboplatin periocular injection

vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2

CEV chemotherapy

Huasheng Yang, M.D, PHD

This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma

This study will be a phase 4 open label interventional case series. Patients with retinoblastoma will be receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive chemotherapy on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 18 months .

CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma

CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma

measure the event free survival rate for the patients at 18 months: patients that without tumor relapse or metastasis

Sun Yat-sen University

Huasheng Yang

CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection

carboplatin periocular injection: chemotherapy together with/without 20mg/2ml carboplatin periocular injection

CEV chemotherapy: vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2

CEV With/Without Carboplatin-Stage 2

CEV With/Without Carboplatin-Stage 3

CEV With/Without Carboplatin

Age, Continuous

Sex: Female, Male

China

Region of Enrollment

stage II

stage IIIa

Number of Participants

CEV With/Without Carboplatin- Stage 2

CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection carboplatin periocular injection: chemotherapy together with/without 20mg/2ml carboplatin periocular injection CEV chemotherapy: vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2

CEV With/Without Carboplatin - Stage 3

Event Free Survival Rate

Overall Study

20mg/2ml carboplatin periocular injection together with CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)

Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months

20mg/2ml carboplatin periocular injection together with chemotherapy

Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.

chemotherapy

Huasheng Yang, Doctor

This study will evaluate the clinical efficacy of periocular injections of carboplatin together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy alone.

This study will be a phase Ⅲ open label interventional case series. Patients with retinoblastoma will be randomized to receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive carboplatin periocular on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 24 months .

Carboplatin Periocular Injection for Retinoblastoma

Carboplatin Periocular Injection in the Treatment for Retinoblastoma--A Single Center, Randomized Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma

measure the mortality rate for the two groups(Cancer-related death and non-Cancer-related death) at two years

Measure the side effects(systemic check-up, local side effects) before each treatment, and 1,3,6,9,12,18,24 months after the treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma	NCT02319486	Retinoblastoma	carboplatin per... CEV chemotherap...	-	Sun Yat-sen University
Carboplatin Periocular Injection for Retinoblastoma	NCT02137928	Retinoblastoma	carboplatin per... chemotherapy	-	Sun Yat-sen University
CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma	NCT02319486	Retinoblastoma	carboplatin per... CEV chemotherap...	-	Sun Yat-sen University

Spots Global Cancer Trial Database for carboplatin periocular injection